halofuginone has been researched along with Prostatic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Genin, O; Iluz, M; Kawada, N; Leon, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y; Yoshizato, K | 1 |
Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J | 1 |
2 other study(ies) available for halofuginone and Prostatic Neoplasms
Article | Year |
---|---|
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Fibroblasts; Humans; Male; Mice; Mice, Nude; Muscles; Myoblasts; Piperidines; Prostatic Neoplasms; Quinazolinones; Taxoids; Tumor Cells, Cultured; Wilms Tumor | 2007 |
Growth inhibition of prostate cancer xenografts by halofuginone.
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones | 2002 |